Reflect on the provided data and tweets to anticipate if the closing price of $mrk is going to increase or decrease at 2017-06-06. Kindly respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-05-22,-0.5,0.6,-0.7,0.4,0.4,-0.5,-0.5,-0.6,-1.1,-1.4,-1.5
2017-05-23,-0.9,0.1,-0.9,0.8,0.8,-1.1,-1.1,-1.2,-1.7,-2.0,-2.2
2017-05-24,-0.2,0.4,-0.6,0.6,0.6,-1.1,-1.5,-1.6,-2.1,-2.5,-2.6
2017-05-25,-0.1,0.1,-0.6,0.2,0.2,-0.9,-1.6,-1.6,-2.0,-2.5,-2.7
2017-05-26,0.1,0.4,-0.2,-0.2,-0.2,-0.3,-1.2,-1.3,-1.7,-2.1,-2.4
2017-05-30,-0.2,0.4,-0.5,-0.1,-0.1,-0.0,-0.9,-1.2,-1.4,-1.9,-2.2
2017-05-31,-0.0,0.6,-0.1,0.4,0.4,-0.2,-1.1,-1.4,-1.6,-2.1,-2.4
2017-06-01,-0.3,0.0,-0.6,0.2,0.2,-0.3,-1.0,-1.5,-1.7,-2.1,-2.5
2017-06-02,-0.0,0.2,-0.4,0.3,0.3,-0.5,-1.0,-1.7,-1.8,-2.3,-2.7
2017-06-05,0.4,0.5,-0.6,-0.6,-0.6,0.1,-0.2,-0.9,-1.1,-1.5,-1.9

2017-05-22: rt AT_USER this could be in the top 50 disruptive technologies this year.  #dcvax $nwbo $juno $kite $blue $agio $celg $gild $bmy $nvs¡­|rt AT_USER key chmp opinions/regulatory filings and ema meetings
2017-05-23: #merck announces thirdquarter 2017 dividend. read more:  $mrk|rt AT_USER keytruda approval juggernaut rolls on, as AT_USER okays use in any solid tumor marked by a genetic feature: |rt AT_USER AT_USER
2017-05-24: rt AT_USER dcvax-l the next disruptive technology.  it will play well with others also.  $nwbo $bmy $mrk $kite $juno $exel $nvs $gild¡­|rt AT_USER dcvax-l the next disruptive technology.  it will play
2017-05-25: rt AT_USER nevada bill to limit diabetes drug prices heads to the governor..  #pharma #diabetes $lly $sny $novo¡­|rt AT_USER nevada bill to limit diabetes drug prices heads to the governor..  #pharma 
2017-05-26: merck &amp; co. target of unusually high options trading $mrk |merck &amp; co. target of unusually high options trading $mrk  #acn|merck &amp; co. target of unusually high options trading $mrk |merck 
2017-05-27: rt AT_USER great increase in trend strength this week with healthcare $abt $mrk $myl $unh $bdx |great increase in trend strength this week with healthcare $abt $mrk $myl $unh $bdx |abstracts out for #
2017-05-28: breakout alert! $mrk watch it on  #videogame #waves|$mrk may face financial fine for anti-competitive pricing |rt AT_USER update: $mrk securities valuation price in technical analysis! ~ #analysis #te
2017-05-29: lots of stocks hitting my scanner for this week.    good month on $pbyi &amp; $mrk as posted on my website. june alerts ?|rt AT_USER $mrk ¡®this is not the end¡¯: experimental therapy that targets gen
2017-05-30: $mrus top presentations to look for at #asco17    $juno $kite $epzm $blue $mrk $pfe $lly $abbv|rt AT_USER nevada bill to limit diabetes drug prices heads to the governor..  ¡­ #pharma #diabetes $lly $
2017-05-31: rt AT_USER AT_USER i remember begging a 70+ year old client to sell $mrk and $ko in 99-00. nothing would convince them. nothing¡­|viking fund management llc has $2.92 million position in merck &amp; c
2017-06-01: rt AT_USER ubs:" immuno-oncology  drugs by target : $mrk $bmy $celg $incy $iph.pa $pfe $amgn $ziop $sgne $ino $clsn ..." |$mrk bullish close on key resistance break and close, at hod, with presentatio
2017-06-02: rt AT_USER being one of the safest drugs is not cheap. in fact, durva is the most expensive. $mrk #asco17 |#merck reports positive results for late-stage trial comparing its keytruda against bristol-.
2017-06-03: rt AT_USER for skeptics the $dvax study is. keynote study. see $mrk pr few weeks ago  |rt AT_USER AT_USER $prtk #uti another very significant market    $agn $mrk that 1-1.3 billion price tag fixing to
2017-06-04: cowen pd-1/pd-l1 market opportunity to exceed $32b in 2022 $mrk $bmy $rog $azn |rt AT_USER missing patients cloud view of $incy ido drug lung cancer study  ¡ª&gt;  #asco17 $mrk|rt AT_USER keynote-059 
2017-06-05: $incy, $mrk provide updates on their cancer combo  #asco17|rt AT_USER keytruda first-line treatment meets primary endpoint in study of advanced bladder cancer patients |rt AT_USER keytruda first-line 
Answer:
Fall